MediJane Holdings Inc. (OTC: MJMD), a medical cannabis marketing and distribution company, recently announced that it has approved the final formulation and branding for its new line of dissolvable oral medical cannabis strips known as Medi-Strips. As an alternative to tablets or pills, the Medi-Strips dissolve upon contact with a wet surface such as the tongue without the need for water.
“Our thing film medicated strips are an orally absorbed, fast acting, dissolvable medical cannabis delivery platform that will provide patients quick and long lasting pain relief,” said CMO Dr. Joseph Cohen. “I am also excited about the extensions into tertiary demographics, such as geriatrics, where oral ingestion and choking hazards [using pills or tablets, for instance] are commonplace.”
Medi-Strips will complement the company’s existing product lines, including its non-drowsy Daytime Pain plus CBD oral capsules and Canna-Mist cannabinoid sprays that have been formulated for treatment of inflammation and chronic, neuropathic, arthritic and back pain. Management believes that smokeless alternatives like these could have a big impact in the $45 billion chronic pain management market.
Currently, patients that want to use these products must have a medical marijuana number from their state and register with the company. Its Daytime Pain plus CBD contains 10mg of CBD and 10mg of THC per capsule, while its Canna-Mist contains 80mg of CBD and 40mg of THC per bottle. Suggested use for both products is a single spray or capsule in the morning to combat pain all day.
The company hasn’t filed a 10-Q or 10-K since its former business Mokita Exploration Ltd. focused on oil and gas exploration and production, but investors could see preliminary financial reports made with the SEC over the coming months.
Shares of MediJane Holdings Inc. jumped 6.25% in early trading on Friday morning, but are trading down nearly 40% so far this year.
Cannabis Financial Network is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing. CFN may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. View Full Disclaimer